Abstract
Radium-223 is a modern radiopharmaceutical with a very good safety profile and therapeutic effect in case of early indication in patients with castration-resistant prostate cancer with symptomatic bone metastatic disease without known visceral metastases and with lymphadenomegaly up to 3cm. Early indication in a few pre-treated patients provides a better chance of all six recommended doses administrations with an effect of prolonging overall survival without worsened quality of life during treatment.
The only relative limitation of the treatment is the need to coordinate the whole procedure with the Nuclear-Medicine professionals, and perhaps excessive concerns from the radiological risk to the environment in their normal life.